AIM2 and neoplasm: Although further experiments are still needed to explore the role of AIM2 in promoting the reprogramming of tumor immune microenvironment, our results suggest that ICIs could be an effective therapeutic strategy to combat the refractory OSCC with AIM2 upregulation.